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ABSTRACT
The Locus Control Region (LCR) of the human globin
gene domain is defined by four erythroid-specific
DNasel hypersensitive sites (HSS) located upstream of
this multigene cluster. The LCR confers copy number
dependent high levels of erythroid specific expression
to a linked transgene, independent of the site of
integration. To assess the role of the individual
hypersensitive sites of the LCR, we have localized
HSS4 to a 280bp fragment that is functional both in
murine erythroleukaemia (MEL) cells and in transgenic
mice. This fragment coincides with the major area of
hypersensitivity 'in vivo' and contains a number of
DNasel footprints. Bandshift analysis shows that these
footprints correspond to binding sites for the erythroid
specific proteins GATAI and NF-E2 and a number of
ubiquitous proteins, including jun/fos, Spl and TEF2.
INTRODUCTION
The human globin gene locus consists of the embryonic e globin
gene, the foetal yGand y genes, and the adult 6 and globin
genes arranged in a 5' to 3' directionl (Fig. 1). A 5kb fragment
containing the human globin gene and flanking regions contains
sufficient information to be expressed in a tissue and
developmentally specific manner in transgenic mice2'3'4, but
expression levels are very low when compared to the endogenous
mouse globin genes. Moreover, the transgenes are highly
susceptible to position effects. A major breakthrough in
overcoming this problem came from the study of a heterozygous
Dutch -y( thalassaemia, which has a 10OKb deletion 5' of the
otherwise unaltered human globin gene5,6'7. This allele is not
expressed in the same cells that express the other (wild type)
allele, suggesting that the sequences governing the expression
of human globin should be contained within the deletion. Four
strong developmentally stable erythroid specific HSS upstream
of the e globin gene8'9 10 were good candidates for such a control
region. To test this possibility the four HSS were linked to a
human globin gene and shown to confer erythroid specific
position independent expression on the transgene in mice at levels
(per gene copy) comparable to the endogenous mouse globin
genes'0. The original construct, termed the minilocus, contained
the four HSS in their natural configuration on a 20Kb fragment
(Fig. 1). This was reduced to 6.5kb without losing the essential
properties of the minilocus, by cloning the individual HSS on
smaller restriction fragments" (Fig. 1, microlocus). This has
allowed us to study the role of each HSS and to characterize the
factors binding to each of the sites.
Stable transformation experiments with individual sites in MEL
cells showed that the major activities were associated with HSS
3 and 212, the latter of which also shows activity in transient
transfections'3. Analysis in transgenic mice confirmed the
properties of HSS 3 and 2, but showed that HSS 4 had a similar
activity to HSS 2. HSS 1 showed very low levels of activity in
both systems in agreement with the observation that a Spanish
6(3 thalassaemial4"5 which has a deletion of HSS 2, 3 and 4
(retaining HSS 1), shows no (3-globin gene activity.
We have previously studied HSS 2 and 3 in detail and shown
that the functional activity of these sites is retained on fragments
coinciding with the region that is hypersensitive in red cells'6"7.
In this paper we have used a similar approach to map the position
of HSS 4 precisely, cloning it as a small fragment and testing
its functional activity in MEL cells and transgenic mice. Full
activity is retained on a 280bp fragment, which contains potential
binding sites for the erythroid-specific factors GATA-1 and
NF-E2 and for several ubiquitous factors including jun/fos, SpI
and the CACC box binding protein TEF2. Binding sites for these
factors also occur in HSS 2 and 316,17, but in a different spatial
organization which may determine the absolute efficiency and/or
developmental specificity of the individual HSS.
MATERIALS AND METHODS
Hypersensitive site mapping
Nuclei were isolated from the MEL clone 5 and L-cell population
200, both containing the minilocus'8 (Fig. iB), as described
previouslyl6. DNA samples were cut with BamHI or XbaI,
Southern blotted and hybridized with a 250bp BamHI-HaelI
fragment (BamHI digestions) or a 290bp BstNI-XbaI fragment
(XbaI digests). The position of the HSS was estimated from the
mobility of Sau3AI double digest fragments and radioactive
X-DNA digested with EcoRI and HindI, or EcoRI, HindIl and
BamHI.
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DNA constructs
Fig. ID depicts the vector GSE 1273 containing the human
,B-globin gene as a 4.8kb BglII fragment and the neomycin-
resistance gene as a selectable marker. The microlocus construct
(GSE 1359) is as previously described". The hypersensitive
area of HSS 4 coincides with a 280bp SstI-AvaI fragment which
was blunted and cloned in the HpaI site of GSE 1273"
(Fig. ID). For transfections, plasmids were linearized with PvuI.
To generate transgenic mice, the SalI-EcoRV fragment containing
the HSS and the human ,B-globin gene was isolated and blunted.
Transgenic mice containing HSS 4 as a 2.1kb BamHI-XbaI
fragment have been described previously'9.
Tissue culture and DNA transfections
The MEL cell line C88 was transfected by electroporation with
20,Ag of linearized plasmid DNA using a Bio-Rad Gene Pulsar
set at 250 V, 960 /%F. All other details are as described20.
Transgenic mice
Constructs were dissolved at a concentration of 1 -42g/mi and
injected into the male pronucleus of fertilized oocytes. 13.5 day
foetuses were dissected and screened by Southern blotting using
the second intron of the human (3-globin gene to detect the
transgene and the 3' ApaI fragment of the endogenous mouse
Thy-I as a loading control. All transgenic foetuses were checked
for mosaicism by comparing the signal of the transgene to that
of the Thy-I gene in DNA samples from body, yolk sac and
placenta from the same foetus. RNA was analyzed by SI nuclease
protection as describedll.
DNaseI footprinting and band shift assays
The 280bp SstI-AvaI fragment was blunted and cloned in both
orientations in the SmaI site of M13 mp8. Other details are as
described previously'6, except that the band shift gels contained
0.5 xTBE. The oligonucleotides used in this study are indicated
in Fig. 4. Competitors were as described'6 or as shown in
Fig. 4.
RESULTS
Fine mapping of hypersensitive site 4
Nuclei were isolated from the MEL clone 5 and the L-cell
population 200, both of which have been stably transfected with
the minilocus (Fig. 1) as described previously'8'2' and treated
with different amounts of DNaseI. After purification, the DNA
was digested with either BamHI or XbaI, Southern blotted and
hybridized with the 250bp BamHI-HaelH and the 290bp BstNI-
XbaI fragments, respectively (Fig. 2). A clear area of
hypersensitivity is found in erythroid cells only, at similar DNaseI
concentrations as had been previously noted for HSS 2 and 3.
There is no apparent change in HSS 4 after induction of MEL
differentiation with DMSO (not shown). The same construct in
non-erythroid L-cells does not display this hypersensitivity.
From comparisons with the mobility of Sau3AI double digest
bands, we conclude that HSS 4 maps from 650 to 900bp from
the 5' BaniHI site 'in vivo' and these co-ordinates will be used
henceforth (Fig.4). It is interesting to note that this area falls
almost completely outside the fragment used to construct the so-
called MLAR22. That particular yLAR fragment starts at the PstI
site at 875 and overlaps only with the 3' end of the hypersensitive
area (Fig.4).
Functional analysis of the hypersensitive site
A 280bp SstI-AvaI fragment from 650 to 930bp 3' to the BamHI
site that overlaps with the area of hypersensitivity was blunted
and cloned into the HpaI site at - 800bp in the promoter of the
human 3-globin gene'6 (Fig. 1). This construct and a vector
containing the full microlocus driving the 3-globin genel" or
only a (3-globin gene were linearized with PvuI and three
independent stably transfected MEL cell populations were
generated for each construct by electroporation2*. RNA was
isolated from these populations four days after induction with
DMSO and quantitated by SI nuclease protection analysis (Fig.
3). The level of the human (3-globin test gene with the HSS 4
deletion is considerably lower (approx 4%) than when driven
by the full microlocus, but it is still much higher than the (3 globin
gene without the HSS 4 (Table 1). The 4% level is similar to
that obtained with the much longer 2.1kb BamHI-XbaI fragment
driving the human (3-globin gene'2.
An important feature of LCR elements is that they render
expression of a linked gene independent from its site of integration
in transgenic mice, hence expression levels follow the copy
number of the transgene. Especially at low transcription levels
this characteristic property of the LCR cannot be assayed easily
in MEL cells; transfected cells are selected for G418 resistance,
such that only integration events into active chromatin regions
are observed.
We therefore used the HSS 4 deletion construct to generate
transgenic mice. The construct described above was digested with
SailI and EcoRV (Fig. 1), blunted, gel purified and injected into
the male pronucleus of fertilized mouse eggs. Foetuses were
analyzed 13.5 days after transfer of the eggs and transgenic
foetuses were identified by Southern blots of EcoRI digested
placenta DNA'0; comparison of the transgene signal to that of
the endogenous Thy-I gene allowed an estimation of the transgene
copy number. Each foetus was screened for mosaicism by
comparing the Thy-1/transgene ratio in DNA from the body, yolk
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Fig. 1. The Locus Control Region of the human ,B-globin gene cluster. A) The
human 0-globin gene cluster on the short arm of chromosome 11. Four
hypersensitive sites 5' to the e globin and one 3' to the ,B-globin gene are indicated
by vertical arrows. B) The 'minilocus' described by Grosveld et al. 10 C) The
'microlocus' constructed by Talbot et al. 1 D) The plasmid construct used in this
study. The HSS 4 fragment was cloned in the HpaI site at -800bp. The SalI
and EcoRV sites were used to isolate the fragment for injection in ferfilized mouse
eggs.
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sac and placenta from the same animal. Using these criteria, one
of the five transgenic offspring was highly mosaic (Table 1).
SI analysis of the transgenic mice is presented in Fig. 3. We
note that the animal with the highest copy number (no. 23) was
anaemic, due to chain imbalance caused by overproduction of
human 13-chains' 10 23. The average expression level per gene
copy of mice nos. 9, 19, 23 and 25 is similar to published data
for mice with the 2. lkb HSS 4 fragment19 (Table 1). The only
exception is mouse no. 15, which does not express significant
amounts of human j-globin mRNA. This is explained by the fact
that the transgene could not be detected in body DNA, although
both the placenta and the yolk sac were positive. Therefore, this
foetus is mosaic with a very low, if any, contribution of the
transgene to the haemapoietic system.
In conclusion, we have shown that the 280bp SstI-AvaI
fragment, overlapping with the hypersensitive area of site 4, is
the functional part of the 2. 1kb fragment used in the
microlocus" . Although it does not confer a high level of
expression to a linked 1-globin gene in MEL cells, it is capable
of conferring integration site independent, copy number
dependent expression in transgenic mice at high levels.
Protein DNA interactions in the 28Obp HSS 4 fragment
Next, we determined protein binding to the functional element
of HSS 4 by DNaseI footprinting in vitro. Fig. 4 shows the
footprints obtained with MEL and HeLa extracts and we find
two footprints, flanking a number of strong hypersensitive sites
which are found with the erythroid extract, but not with the HeLa
cell extract. Six other footprinted areas are found with both
extracts, although some of these are weak. No differences were
found between MEL, foetal liver and adult anaemic spleen
extracts (not shown).
Based on the DNaseI footprinting we designed a number of
oligonucleotides covering the footprinted areas and used these
in bandshift experiments (Fig. 5). Oligonucleotide 870 is a double
GATA-1 binding site, since the shifted products are efficiendly
competed by the -200 GATA-1 site of the human 3-globin
gene24. This is in agreement with the footprinting data (Fig. 4),
since binding of GATA-1 is accompanied by the appearance of
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Fig. 2. Fine mapping of HSS 4 in MEL and L cells. Nuclei were isolated from
MEL cells or L cells containing the minilocust8. DNA from DNaseI treated
nuclei was digested with BamHI (left panel) or XbaI (right panel) and Southern
blotted. A double digestion of Sau3AI and BamHI or XbaI was used as an internal
reference (lanes Sau3). The amount of DNaseI (.ug/mg DNA) is indicated.
Radiolabelled X restriction fragments were used as markers. The black bar indicates
the hypersensitive area. The left two panels were probed with the 5' BamHI-
HaeIII fragment, the right two panels with the 3' BstNI-XbaI fragment.
induced MEL cells transgenic mice
Fig. 3. Quantitative SI analysis of the hypersensitive site 4. 5 Fg of total RNA
from induced MEL cell populations, or approximately l,ug of total 13.5 day foetal
liver RNA was used per lane. 151tg total RNA from the microlocus population
C (3 xC) was included to monitor probe excess. Protected fragments, specific
for the 5' ends of mouse a globin and human 03-globin mRNA are indicated.
ntg = non-transgenic control, C = control with 2.1kb BamHI-XbaI microlocus
fragment'9. Relative specific activity of the probes was Hu,B: MCa = 1.47.
Table 1. Expression of the hypersensitive site 4 construct in MEL cells and
transgenic mice. Bands were cut out of the gel and Cerenkov counted. A similar
sized gel fragment just above the band of interest was also counted for background
correction. The data given are corrected for the relative specific activities of the
probes used. Copy numbers of the transgenic animals were determined from
Southern blots. The copy number range in MEL cells was between 2 and 3 copies.
S1 analysis HSS4
MEL cells
Construct Sample Hu3/Ma Average % y locus
A HS4 A 0.044 0.062 4
B 0.067
C 0.074
no LCR A 0.005 0.004 0.3
B 0.001
C 0.005
Microlocus A 1.624 1.542 100
B 1.189
C 1.813
3xC 1.810
Transgenic mice
Construct Mouse Copy no. Hu/3/Ma Expr./copy
AHS 4 9 3 0.471 0.16
15 mosaic < 1 in body 0.005
19 4 0.462 0.13
23 35-40 4.147 0.12
25 6 0.934 0.16
2.1kb HS4 157 13 1.877 0.14
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Fig. 4. DNaseI footprinting of the 280bp SstI-AvaI fragment. Top: The DNA in the 'no protein' lanes was treated with 1, 0.5, 0.25 and 0. 125,tg DNaseI as indicated.
DNA was pre-incubated with 10 or 50,gg protein and treated with 1 or 21g DNaseI, respectively. Extracts were derived from MEL or HeLa cells as indicated.
Both sense and antisense strands are shown. Footprinted regions are indicated by bars alongside the figure. A sequence ladder (lanes G,A,T and C) was used to
map the footprints on the sequence. Bottom: Summary of the footprints and oligonucleotides. Shaded areas indicate footprints, brackets indicate the oligonucleotides
used for bandshifts (Fig. 5). Black bars indicate consensus sequences for GATA-1 (oligo 870) or NF-E2/jun/fos binding sites (oligo 810).
a strong hypersensitive site on one side of the helix24-27.
Interestingly, the 870 GATA-1 site contains two consensus
binding sites in opposite orientation and from the bandshift
competitions, we conclude that GATA-1 molecules can bind to
both sites simultaneously (Fig. 5, 870 oligo, slower migrating
complex). Similar arrays are found in HSS 2 and 3 of the human
,B-globin LCR'6"17 and in the chicken (3-globin 3' enhancer26'27.
Interestingly the latter has recently been shown to direct copy
number dependent expression of a linked transgene28. The 810
oligonucleotide contains a consensus for jun/fos/NF-E229 which
has previously been shown to be important for the function of
the PBGD promoter30 and the (3 globin HSS 217,31. As shown
in Fig. 5, NF-E2 and jun/fos indeed bind to this sequence 'in
vitro' and we anticipate that the single site in HSS 4 acts as an
enhancing element'7'31.
Two oligonucleotides, 670 and 790, did not show any specific
bandshift in vitro (not shown), while oligonucleotides 700, 840,
890 and 920 bind ubiquitous proteins (Fig. 5). The nature of the
proteins binding to the 700 oligonucleotide are as yet unclear
because the bandshifts were not competed by oligonucleotides
from HSS 2, 3 or the other oligonucleotides of HSS 4. The 840,
890 and 920 oligonucleotides are all capable of binding the
general transcription factors Spl32 and the CACC box binding
protein TEF-233 (Fig. 5). In addition, oligonucleotide 840 binds
J-BP, a factor also found in HSS 2 and 3, as demonstrated by
the competition for binding using the J-BP binding site from the
HSS 2 (Fig. 5, panel 840). These general transcription factors
may be required for proper functioning of HSS 4, contributing
to its tissue-specific character via synergistic interactions with
GATA-1 and NF-E2.
......... .. ..
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Fig. 5. Bandshift analysis of HSS 4. Oligonucleotide probes covering the footprinted areas (see Fig. 4) were used in gel retardation assays using MEL, foetal liver
or HeLa extracts. Approximately 5yg extract was used per lane. Competitors were added as indicated in 100-fold molar excess prior to the addition of extract to
the reaction. Sequences of the probes and competitors are given in Fig. 4 or have been described; -indicates no competitor. GATAl competitor contains the -200
region of the human ,B-globin gene24; 2xNF-E2 is the HSS2 NF-E2 binding site37. 5'NF-E2 is the NF-E2 site of HSS 316; PBGD & cfos are the NF-E2 binding
sites from the PBGD & cfos gene promoters29Y30; TATA competitor contains the (3-globin gene TATA box24. SpI competitor32, CAAT24 and CACC boxt6 competitors
have been described. The H and J competitors contain binding sites for the H-BP and J-BP proteins of HSS217 37 *Spl represents an Spi-like factor and has been
discussed previously'6. The band running below J-BP in the panel with oligo 840 is not reproducible in every MEL extract and is most likely a degradation product.
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DISCUSSION
In this paper we have delineated the functional element of HSS
4 of the human (3-globin LCR. We demonstrate that it coincides
with the major area of hypersensitivity in erythroid cells, as we
have shown previously for HSS 2 and 316,17. The basic
properties of the HSS 4 are retained on a 280bp fragment, which
confers position independent expression on a linked human (3-
globin gene. An interesting feature of HSS 4 is that the relative
expression level of a linked (3-globin gene is higher in 13.5 day
foetal liver than in MEL cells, indicating that the individual HSS
of the LCR may have different developmental specificities. It
should be noted that in the case of HSS 4, the functional region
we have mapped in this paper is virtually absent from the ,uLAR
construct22. As a consequence developmental studies using only
the AtLAR may have to be treated with caution. We are currently
investigating the role of the individual HSS in the developmental
profile of the human (3-globin gene cluster (Fraser, Dillon and
Lindenbaum, unpublished results) and characterization of all the
sequences involved will, hopefully, enable us to propose a concise
model explaining the spatial and temporal expression patterns
of the individual genes in the human ,B-globin gene cluster at the
molecular level.
The proteins binding to the 280bp HSS 4 fragment show a high
degree of similarity to those found interacting with the minimal
fragments of HSS 2 and 316,17. We have shown that the presence
of binding sites for the erythroid (and megakaryocytic34) specific
transcription factor NF-E2 is not sufficient for position
independent expression of the transgene in mice in the case of
HSS 217, although it is certainly required for the high levels of
expression'7'31. It is also known that although GATAl is a
transactivator35, the presence of GATA-1 binding sites per se
is insufficient to give position independent expression. The 5'
and 3' regions of the human (3 globin gene contain at least six
GATA-1 binding sites24'25, but do not confer integration site
independent expression on the (3-globin gene2'3'4. However it is
interesting to note that HSS 4 contains two closely spaced GATA
1 sites in opposite orientation, a feature which is also observed
in a number of other elements conferring position independent
expression, i.e. HSS 217 and 316 and the chicken (3 globin
enhancer28. It is possible that GATA 1 requires an interaction
with itself or one of the other GATA proteins to achieve this
effect36. All the other factors interacting with LCR sequences
which have been identified thus far are ubiquitous proteins,
indicating that a combination of erythroid-specific and ubiquitous
factors is required to render the ,B-globin gene independent of
its site of integration'6"17. The (abundant) ubiquitous factors
shared by the three HSS of the LCR studied to date are Spl and
TEF-2, but a simple multimerized combination of a GATA-1
and an Spl/TEF-2 binding site is not functional (S.Philipsen,
unpublished results). It is, therefore, conceivable that other, as
yet less well characterised factors are involved, e.g. J-BP37. In
addition, some factors may not be very abundant or soluble and
could be overlooked in DNaseI and bandshift experiments with
crude nuclear extracts. We are currently fractionating erythroid
extracts to address at least the first part of this question.
The work described in this paper is one step further in the
analysis of the (-globin LCR. Interestingly, similar sequences
have recently been described for the human a-globin genes38
and a detailed analysis of these sequences may aid our
understanding of the regulation of these two gene families.
Transcription from (-like and a-like gene clusters has to be
activated co-ordinately throughout development and adult life to
prevent chain imbalance. Since the LCRs play an important part
in the absolute transcription level of individual genes and appear
to be similar, they probably provide the key to understanding
the coordinated expression of the genes from both clusters.
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